“
TL;DR
The authors discuss immunomodulatory and antioxidant drug candidates that have shown promise in preclinical studies for promoting neuroprotection and RGC survival.
Pharmaceuticals · 3 authors, 1 centre
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The authors discuss immunomodulatory and antioxidant drug candidates that have shown promise in preclinical studies for promoting neuroprotection and RGC survival.
The authors discuss immunomodulatory and antioxidant drug candidates that have shown promise in preclinical studies for promoting neuroprotection and RGC survival. A key implication is that these therapies may target glaucoma independently of IOP, which is the current primary treatment focus. The authors note that balancing pro- and anti-inflammatory and pro- and anti-apoptotic processes is critical to avoid unintended detrimental effects, and that maintaining redox balance is essential for cellular homeostasis. Limitations include the translational gap between preclinical and clinical outcomes, challenges with biomarker sensitivity, long-term follow-up, and drug bioavailability. The review concludes that immunomodulatory agents and antioxidants represent a significant opportunity to complement established IOP-lowering drugs, though further research and clinical trials are needed.